Chronic myelogenous leukemia

Chronic Myeloid Leukemia Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 1, 2022
Health, Oncology, GlobalData, Myelocyte, Cell, Profile, Man, Sex, Epidemiology, Acute leukemia, Chronic myelogenous leukemia, Bone marrow, Mayo Clinic, Woman, Population, Cancer, Atypical chronic myeloid leukemia, Lymphocyte, Risk, Blood, American Cancer Society, Doctor of Philosophy, AGR, Therapy, CML, Mutation, Vaccine, Dietary supplement, Management, Pharmaceutical industry

The "Chronic Myeloid Leukemia (CML) - Epidemiology Forecast to 2030" GlobalData report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Myeloid Leukemia (CML) - Epidemiology Forecast to 2030" GlobalData report has been added to ResearchAndMarkets.com's offering.
  • The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CML.
  • The report also provides a 10-year epidemiological forecast of the 20-year diagnosed prevalent cases of CML.
  • The Chronic Myeloid Leukemia (CML) Epidemiology Report provides an overview of the risk factors and global trends of CML in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).

Belong.Life Creates Dedicated Chronic Myeloid Leukemia Community Within World's Largest Cancer App

Retrieved on: 
Tuesday, January 11, 2022
Human sexuality, Patient, Technology, Acute leukemia, Chronic myelogenous leukemia, Leukemia, Disease, Roger Hawkins (drummer), Bone marrow, CML, Caregiver, Education, Quality of life, MS, AI, Cancer, Hospital, Medical device, Insurance, Belong

NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Belong.Life , a developer of social and professional networks for managing and navigating various diseases and patient journeys, announced today the launch of a dedicated community for chronic myeloid leukemia (CML) patients on its Belong-Beating Cancer Together app.

Key Points: 
  • NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Belong.Life , a developer of social and professional networks for managing and navigating various diseases and patient journeys, announced today the launch of a dedicated community for chronic myeloid leukemia (CML) patients on its Belong-Beating Cancer Together app.
  • Chronic myeloid leukemia, also known as chronicmyelogenousleukemia, is a slow-progressing cancer that originates in the bone marrow, typically affecting older adults.
  • With CML comprising about 15% of new leukemia diagnoses in the U.S., Belong.Life receivednumerous requests from patients and caregivers to create a community specific to this disease.
  • The new community will feature a designated folder with updated educational content customized to CML patients and caregivers.

Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Retrieved on: 
Tuesday, December 14, 2021
Forward-looking statement, Hospital, Fluconazole, McNeil Consumer Healthcare, Aplastic anemia, FDA, NDA, QIDP, Mycosis, Restore, Physician, Securities Exchange Act of 1934, Drug Quality and Security Act, Candidiasis, Private Securities Litigation Reform Act, Transplant, COVID-19, Securities Act of 1933, Integrity, U.S. Securities and Exchange Commission, Safety, Posaconazole, Patient, Therapy, Security (finance), Pain management, Chronic myelogenous leukemia, Acute lymphoblastic leukemia, Lymphoma, Acute myeloid leukemia, New Shrimadhopur DFC Station, Webcast, Fungemia, Heart, Pharmaceutical industry, Respect, Pneumocystidomycetes, Aspergillus

SAN DIEGO and CAMBRIDGE, United Kingdom, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis.

Key Points: 
  • The trial is enrolling adults with underlying conditions including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndrome(s), lymphoma and aplastic anemia.
  • The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients.
  • Cidara has completed a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and is currently conducting a second Phase 3 clinical trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).
  • Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East.

Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Retrieved on: 
Tuesday, December 14, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Forward-looking statement, Hospital, U.S. Securities and Exchange Commission, Fluconazole, McNeil Consumer Healthcare, Aplastic anemia, FDA, NDA, QIDP, Mycosis, Restore, Physician, Securities Exchange Act of 1934, Drug Quality and Security Act, Community, Candidiasis, Private Securities Litigation Reform Act, Food and Drug Administration, Transplant, European Commission, COVID-19, Epidemiology, Securities Act of 1933, Integrity, Safety, Posaconazole, Patient, Therapy, Security (finance), Pain management, Chronic myelogenous leukemia, Acute lymphoblastic leukemia, Lymphoma, Risk, Acute myeloid leukemia, DFC (cipher), Webcast, Fungemia, Heart, Pharmaceutical industry, Animal, Respect, Pneumocystidomycetes, Aspergillus

Invasive candidiasis (IC) continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems.

Key Points: 
  • Invasive candidiasis (IC) continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems.
  • The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients.
  • Cidara has completed a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and is currently conducting a second Phase 3 clinical trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).
  • Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East.

InsightRX's Precision Medicine Technology to Help Improve Care for Patients Receiving Stem Cell Transplants

Retrieved on: 
Monday, November 22, 2021
Patient, Tissue, University of California, San Francisco, CEO, SOS, Cancer, Vein graft failure, Leukemia, Busulfan, Chronic myelogenous leukemia, Death, ATG, AML, Health, Packera aurea, Precision medicine, Transplant, Acute myeloid leukemia, Doctor of Philosophy, SAN, MSK, University, Metabolism, UCSF, Machine learning, Memorial Sloan Kettering Cancer Center, Research, CML, Apollo, Adult, Degenerative disease, Here Comes the Sun, Mortality, Pharmacy, Graft-versus-host disease, Infection, San Francisco, Liver, Lymphatic system, Pharmaceutical industry

The InsightRX Nova platform helps to select patient-specific doses of the chemotherapy drugs busulfan and fludarabine, as well as the immunosuppressant anti-thymocyte globulin (ATG), for adult and pediatric patients receiving stem cell transplants.

Key Points: 
  • The InsightRX Nova platform helps to select patient-specific doses of the chemotherapy drugs busulfan and fludarabine, as well as the immunosuppressant anti-thymocyte globulin (ATG), for adult and pediatric patients receiving stem cell transplants.
  • Stem cell transplants typically are preceded by a chemotherapeutic conditioning regimen that destroys cancer cells and suppresses a patient's immune response to the donor cells.
  • The five-year cumulative mortality rate for leukemia patients receiving a stem cell transplant is about 50%, with relapse, infection, and GvHD as the leading causes of death.
  • InsightRX is a healthcare technology company that has developed a cloud-based platform for precision medicine and clinical analytics designed to individualize treatment at the point of care.

Kintara Announces Changes to Executive Leadership Team

Retrieved on: 
Tuesday, November 9, 2021
NDA, Traffic barrier, Lung cancer, Private Securities Litigation Reform Act, Therapy, Director, SAN, CEO, Wilms' tumor, CMBC, Technology, National Foundation for Cancer Research, EMA, Sumathi Best Television Current Reporting Award, GBM, Blood, Ovarian cancer, Chronic myelogenous leukemia, Growth, Senior, COVID-19, MGMT, Research, Annual report, Board, Medulloblastoma, Company, National Brain Tumor Society, United Nations Foundation, Brain, SEC, Heron, Financial Accounting Standards Board, Physician, Lung, St. Bonaventure University, Marketing, Patient, FDA, Orphan, Management, Pharmaceutical industry

"I joined Kintara based on my belief in VAL-083's potential to be a game-changing therapeutic agent.

Key Points: 
  • "I joined Kintara based on my belief in VAL-083's potential to be a game-changing therapeutic agent.
  • Robert E. Hoffman has served as a director of Kintara since April 2018 and Chairman since June 2018.
  • Kintara has sufficient funding through stage 1, which could result in graduation to the final confirmatory stage, the potential NDA-enabling portion of the study.
  • Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer (CMBC).

Global Chronic Myeloid Leukemia Report 2021 - Develop In-depth Knowledge of Competition and Markets - ResearchAndMarkets.com

Retrieved on: 
Monday, October 25, 2021
Health, Pharmaceutical, Competitive landscape, Research, Epidemiology, G7, Prevalence, Atypical chronic myeloid leukemia, Chronic myelogenous leukemia, Poultry, Pharmaceutical industry

The "Global Chronic Myeloid Leukemia Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chronic Myeloid Leukemia Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into Chronic Myeloid Leukemia pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Chronic Myeloid Leukemia treatment options, Chronic Myeloid Leukemia late-stage clinical trials pipeline, Chronic Myeloid Leukemia prevalence by countries, Chronic Myeloid Leukemia market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Chronic Myeloid Leukemia pipeline: Find out drugs in clinical trials for the treatment of Chronic Myeloid Leukemia by development phase 3, phase 2, by pharmacological class and company
    Chronic Myeloid Leukemia drugs: Identify key drugs marketed and prescribed for Chronic Myeloid Leukemia in the US, including trade name, molecule name, and company
    Chronic Myeloid Leukemia drugs sales: Find out the sales value for Chronic Myeloid Leukemia drugs by countries
    Chronic Myeloid Leukemia market valuations: Find out the market size for Chronic Myeloid Leukemia drugs in 2020 by countries.

Europe Chronic Myeloid Leukemia Market and Competitive Landscape Report 2021: Pipeline, Epidemiology, Valuations, Forecasts, Drug Sales, Drug Forecasts, and Market Shares 2018-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 25, 2021
Health, Other Health, Competitive landscape, Research, Epidemiology, Prevalence, Atypical chronic myeloid leukemia, Chronic myelogenous leukemia, Poultry, Pharmaceutical industry

The "Europe Chronic Myeloid Leukemia Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Chronic Myeloid Leukemia Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Europe Chronic Myeloid Leukemia Market and Competitive Landscape - 2021, provides comprehensive insights into Chronic Myeloid Leukemia pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Chronic Myeloid Leukemia treatment options, Chronic Myeloid Leukemia late-stage clinical trials pipeline, Chronic Myeloid Leukemia prevalence by countries, Chronic Myeloid Leukemia market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Chronic Myeloid Leukemia pipeline: Find out drugs in clinical trials for the treatment of Chronic Myeloid Leukemia by development phase 3, phase 2, by pharmacological class and company
    Chronic Myeloid Leukemia drugs: Identify key drugs marketed and prescribed for Chronic Myeloid Leukemia in the US, including trade name, molecule name, and company
    Chronic Myeloid Leukemia drugs sales: Find out the sales value for Chronic Myeloid Leukemia drugs by countries
    Chronic Myeloid Leukemia market valuations: Find out the market size for Chronic Myeloid Leukemia drugs in 2020 by countries.

Global Blood Platelets Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 11, 2021
Health, Biotechnology, Bleeding, Patient, CDC, Multiple myeloma, Korea Disease Control and Prevention Agency, United Kingdom, American Cancer Society, Organization, Center, Cancer, Cancer Research UK, Chronic myelogenous leukemia, Platelet transfusion, World Blood Donor Day, Prevalence, Cancer research, Awareness, Platelet, RBC, Growth, American Red Cross, Blood product

Chronic myelogenous leukemia and multiple myeloma cancers lead to the development of acquired platelet function disorders in some cancer patients.

Key Points: 
  • Chronic myelogenous leukemia and multiple myeloma cancers lead to the development of acquired platelet function disorders in some cancer patients.
  • This is majorly attributed to the factors such as the presence of several organizations engaged in the distribution of blood components.
  • In addition, the number of platelet transfusions in the region has boosted the demand for blood platelets.
  • Thus, in view of the above-mentioned factors, the blood platelets market is anticipated to grow significantly over the forecast period in North America.

Global Chronic Myeloid Leukemia Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 12, 2021
Health, Oncology, Acute myeloid leukemia, Chronic myeloid leukemia, Leukemia, Cancer, Chronic myelogenous leukemia, Medicine, Myeloid leukemia, Medical specialties, Chronic condition, Leukostasis, Myeloid sarcoma

b'The "Global Chronic Myeloid Leukemia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Chronic Myeloid Leukemia Epidemiology and Patient Flow Analysis - 2021, provides Chronic Myeloid Leukemia epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Chronic Myeloid Leukemia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Chronic Myeloid Leukemia Epidemiology and Patient Flow Analysis - 2021, provides Chronic Myeloid Leukemia epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Chronic Myeloid Leukemia patients, history of the disease at the population level (Chronic Myeloid Leukemia prevalence, Chronic Myeloid Leukemia incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nChronic Myeloid Leukemia patient flow: Chronic Myeloid Leukemia prevalence, diagnosed, and drug-treated patients\nDemographics: Chronic Myeloid Leukemia patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Chronic Myeloid Leukemia market sizing, assessing market potential, and developing drug forecast models\nIdentify Chronic Myeloid Leukemia patients segments through age groups, gender, and disease sub-types\nEvaluate Chronic Myeloid Leukemia market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005856/en/\n'